These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 31256145)

  • 21. Mapping neurodegeneration across the Huntington's disease spectrum: a five-year longitudinal analysis of plasma neurofilament light.
    Parkin GM; Thomas EA; Corey-Bloom J
    EBioMedicine; 2024 Jun; 104():105173. PubMed ID: 38815362
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Progression of motor subtypes in Huntington's disease: a 6-year follow-up study.
    Jacobs M; Hart EP; van Zwet EW; Bentivoglio AR; Burgunder JM; Craufurd D; Reilmann R; Saft C; Roos RA;
    J Neurol; 2016 Oct; 263(10):2080-5. PubMed ID: 27435968
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of symbol digit modality test score extremes in Huntington's disease.
    Braisch U; Muche R; Rothenbacher D; Landwehrmeyer GB; Long JD; Orth M;
    Am J Med Genet B Neuropsychiatr Genet; 2019 Apr; 180(3):232-245. PubMed ID: 30788902
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials.
    ; Biglan KM; Shoulson I; Kieburtz K; Oakes D; Kayson E; Shinaman MA; Zhao H; Romer M; Young A; Hersch S; Penney J; Marder K; Paulsen J; Quaid K; Siemers E; Tanner C; Mallonee W; Suter G; Dubinsky R; Gray C; Nance M; Bundlie S; Radtke D; Kostyk S; Baic C; Caress J; Walker F; Hunt V; O'Neill C; Chouinard S; Factor S; Greenamyre T; Wood-Siverio C; Corey-Bloom J; Song D; Peavy G; Moskowitz C; Wesson M; Samii A; Bird T; Lipe H; Blindauer K; Marshall F; Zimmerman C; Goldstein J; Rosas D; Novak P; Caviness J; Adler C; Duffy A; Wheelock V; Tempkin T; Richman D; Seeberger L; Albin R; Chou KL; Racette B; Perlmutter JS; Perlman S; Bordelon Y; Martin W; Wieler M; Leavitt B; Raymond L; Decolongon J; Clarke L; Jankovic J; Hunter C; Hauser RA; Sanchez-Ramos J; Furtado S; Suchowersky O; Klimek ML; Guttman M; Sethna R; Feigin A; Cox M; Shannon B; Percy A; Dure L; Harrison M; Johnson W; Higgins D; Molho E; Nickerson C; Evans S; Hobson D; Singer C; Galvez-Jimenez N; Shannon K; Comella C; Ross C; Saint-Hilaire MH; Testa C; Rosenblatt A; Hogarth P; Weiner W; Como P; Kumar R; Cotto C; Stout J; Brocht A; Watts A; Eberly S; Weaver C; Foroud T; Gusella J; MacDonald M; Myers R; Fahn S; Shults C
    JAMA Neurol; 2016 Jan; 73(1):102-10. PubMed ID: 26569098
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Deciphering Cognitive Impairments in Huntington's Disease: A Comparative Study of Stroop Test Variations.
    Sierra LA; Wynn A; Lanzaro E; Dzekon K; Russell A; Halko M; Claassen DO; Frank S; Considine CM; Laganiere S
    J Huntingtons Dis; 2024; 13(2):249-257. PubMed ID: 38759020
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Associations between prognostic index scores and plasma neurofilament light in Huntington's disease.
    Parkin GM; Corey-Bloom J; Long JD; Snell C; Smith H; Thomas EA
    Parkinsonism Relat Disord; 2022 Apr; 97():25-28. PubMed ID: 35276585
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Huntington's Disease Progression: A Population Modeling Approach to Characterization Using Clinical Rating Scales.
    Sun W; Zhou D; Warner JH; Langbehn DR; Hochhaus G; Wang Y
    J Clin Pharmacol; 2020 Aug; 60(8):1051-1060. PubMed ID: 32416008
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ancillary Service Utilization and Impact in Huntington's Disease.
    Yomtoob J; Yeh C; Bega D
    J Huntingtons Dis; 2019; 8(3):301-310. PubMed ID: 31177235
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predictors of Working Capacity Changes Related to Huntington's Disease: A Longitudinal Study.
    van der Zwaan KF; Jacobs M; van Zwet EW; Roos RAC; de Bot ST
    J Huntingtons Dis; 2021; 10(2):269-276. PubMed ID: 33523014
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Defining Clinical Meaningfulness in Huntington's Disease.
    Hamilton JL; Mills JA; Stebbins GT; Long JD; Fuller RLM; Sathe S; Roché M; Sampaio C
    Mov Disord; 2023 Jun; 38(6):1036-1043. PubMed ID: 37147862
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Motor dysfunction influence on executive functioning in manifest and premanifest Huntington's disease.
    Hart EP; Dumas EM; Schoonderbeek A; Wolthuis SC; van Zwet EW; Roos RA
    Mov Disord; 2014 Mar; 29(3):320-6. PubMed ID: 24500841
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Machine learning in Huntington's disease: exploring the Enroll-HD dataset for prognosis and driving capability prediction.
    Ouwerkerk J; Feleus S; van der Zwaan KF; Li Y; Roos M; van Roon-Mom WMC; de Bot ST; Wolstencroft KJ; Mina E
    Orphanet J Rare Dis; 2023 Jul; 18(1):218. PubMed ID: 37501188
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence, course, and predictors of apathy in Huntington's disease: a two-year prospective study.
    Reedeker N; Bouwens JA; van Duijn E; Giltay EJ; Roos RA; van der Mast RC
    J Neuropsychiatry Clin Neurosci; 2011; 23(4):434-41. PubMed ID: 22231315
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biological and clinical manifestations of juvenile Huntington's disease: a retrospective analysis.
    Fusilli C; Migliore S; Mazza T; Consoli F; De Luca A; Barbagallo G; Ciammola A; Gatto EM; Cesarini M; Etcheverry JL; Parisi V; Al-Oraimi M; Al-Harrasi S; Al-Salmi Q; Marano M; Vonsattel JG; Sabatini U; Landwehrmeyer GB; Squitieri F
    Lancet Neurol; 2018 Nov; 17(11):986-993. PubMed ID: 30243861
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The use of quantitative oculometry in the assessment of Huntington's disease.
    Ali FR; Michell AW; Barker RA; Carpenter RH
    Exp Brain Res; 2006 Feb; 169(2):237-45. PubMed ID: 16273398
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety, tolerability, and efficacy of PBT2 in Huntington's disease: a phase 2, randomised, double-blind, placebo-controlled trial.
    Huntington Study Group Reach2HD Investigators
    Lancet Neurol; 2015 Jan; 14(1):39-47. PubMed ID: 25467848
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modeling longitudinal change in motor and cognitive processing speed in presymptomatic Huntington's disease.
    Maroof DA; Gross AL; Brandt J
    J Clin Exp Neuropsychol; 2011 Oct; 33(8):901-9. PubMed ID: 21644140
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Late-onset Huntington's disease: diagnostic and prognostic considerations.
    Koutsis G; Karadima G; Kladi A; Panas M
    Parkinsonism Relat Disord; 2014 Jul; 20(7):726-30. PubMed ID: 24721491
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Unified Huntington's disease rating scale: a follow up.
    Siesling S; van Vugt JP; Zwinderman KA; Kieburtz K; Roos RA
    Mov Disord; 1998 Nov; 13(6):915-9. PubMed ID: 9827615
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The potential of composite cognitive scores for tracking progression in Huntington's disease.
    Jones R; Stout JC; Labuschagne I; Say M; Justo D; Coleman A; Dumas EM; Hart E; Owen G; Durr A; Leavitt BR; Roos R; O'Regan A; Langbehn D; Tabrizi SJ; Frost C
    J Huntingtons Dis; 2014; 3(2):197-207. PubMed ID: 25062862
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.